retatrutide obesity trial results phase 3 just came out and the are genuinely insane: - 28.3% bodyweight lost on 12mg over 80 weeks Retatrutide: The Triple Agonist That's
Pay in 4 interest-free payments of $5.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Live Spec
Retatrutide: The Triple Agonist That's Redrawing the Map of Obesity Medicine BREAKING: Retatrutide Shows Bariatric Level Weight Loss in Phase 3 Trial New Phase 3 TRIUMPH 1 data show retatrutide may deliver weight loss outcomes approaching those seen with bariatric surgerymarking one of the most Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial Retatrutide just delivered the most powerful weight loss data ever recorded in a Phase 3 obesity trial. At 104 weeks, participants on the 12 mg dose lost an average of 85 pounds. HOT OFF THE PRESS: Retatrutide Phase 3 data has arrived and the obesity medicine world is paying attention. In Lilly's TRIUMPH 1 trial, participants receiving the highest dose achieved an average VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity 2 Minute Medicine
Store: www.ab-travaux.com · Domain: www.ab-travaux.com
























